CY1125117T1 - Ενωσεις μορφολινυλπυριδονης - Google Patents
Ενωσεις μορφολινυλπυριδονηςInfo
- Publication number
- CY1125117T1 CY1125117T1 CY20221100283T CY221100283T CY1125117T1 CY 1125117 T1 CY1125117 T1 CY 1125117T1 CY 20221100283 T CY20221100283 T CY 20221100283T CY 221100283 T CY221100283 T CY 221100283T CY 1125117 T1 CY1125117 T1 CY 1125117T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- morpholinylpyridone
- formula
- diseases
- diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η εφεύρεση παρέχει καινοφανείς ενώσεις μορφολινυλπυριδόνης του χημικού τύπου (Ι), φαρμακευτικές συνθέσεις που περιέχουν τέτοιες ενώσεις, και μεθόδους για χρήση τέτοιων ενώσεων σε αγωγή παθήσεων που συμπεριλαμβάνουν καρκίνο, διαβήτη τύπου II, φλεγμονώδεις παθήσεις, αυτοάνοσες παθήσεις, νευροεκφυλιστικές διαταραχές, καρδιαγγειακές διαταραχές και ιικές λοιμώξεις˙ Χημικό τύπο (Ι) όπου τα R1, R2 και Α καθορίζονται ως στην προδιαγραφή.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187567 | 2017-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125117T1 true CY1125117T1 (el) | 2024-12-13 |
Family
ID=59686888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100283T CY1125117T1 (el) | 2017-08-23 | 2022-04-14 | Ενωσεις μορφολινυλπυριδονης |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11560374B2 (el) |
| EP (2) | EP4056569A1 (el) |
| JP (2) | JP7199736B2 (el) |
| KR (1) | KR102732013B1 (el) |
| CN (3) | CN116444510A (el) |
| AU (2) | AU2018320419B2 (el) |
| CY (1) | CY1125117T1 (el) |
| DK (1) | DK3672962T3 (el) |
| ES (1) | ES2910157T3 (el) |
| HR (1) | HRP20220497T1 (el) |
| HU (1) | HUE058661T2 (el) |
| IL (3) | IL302077A (el) |
| LT (1) | LT3672962T (el) |
| PL (1) | PL3672962T3 (el) |
| PT (1) | PT3672962T (el) |
| RS (1) | RS63109B1 (el) |
| SI (1) | SI3672962T1 (el) |
| SM (1) | SMT202200169T1 (el) |
| TW (2) | TWI803511B (el) |
| WO (1) | WO2019038390A1 (el) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022115543A1 (en) * | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of vps34 inhibitors |
| CA3199995A1 (en) * | 2020-11-25 | 2022-06-02 | Daniel L. Flynn | Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection |
| US12414955B2 (en) | 2020-11-25 | 2025-09-16 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of VPS34 inhibitors |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006034473A2 (en) * | 2004-09-23 | 2006-03-30 | Reddy Us Therapeutics, Inc. | Novel pyrimidine compounds, process for their preparation and compositions containing them |
| WO2011058478A1 (en) * | 2009-11-16 | 2011-05-19 | Pfizer Inc. | Substituted triazolopyrimidines as pde8 inhibitors |
| JP2014500308A (ja) | 2010-12-21 | 2014-01-09 | ノバルティス アーゲー | Ｖｐｓ３４阻害剤としてのビヘテロアリール化合物 |
| EP2655375B1 (fr) | 2010-12-23 | 2014-12-03 | Sanofi | Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique |
| FR2969612B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| FR2992314B1 (fr) * | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| EP3042900B1 (en) * | 2013-08-29 | 2020-09-23 | Fujifilm Corporation | Novel morpholine derivative or salt thereof |
| MX2016009135A (es) | 2014-01-14 | 2016-10-05 | Millennium Pharm Inc | Heteroarilos y usos de estos. |
| US10202373B2 (en) | 2014-01-14 | 2019-02-12 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| WO2017009751A1 (en) | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| HRP20201400T1 (hr) * | 2016-02-19 | 2020-11-27 | Sprint Bioscience Ab | Spojevi 6-aril-4-(morfolin-4-il)-1h-piridin-2-ona korisni za liječenje karcinoma i dijabetesa |
| CN108884067B (zh) | 2016-02-19 | 2021-01-08 | 思普瑞特生物科学公司 | 可用于治疗癌症和糖尿病的6-杂环基-4-吗啉-4-基吡啶-2-酮化合物 |
-
2018
- 2018-08-23 LT LTEPPCT/EP2018/072791T patent/LT3672962T/lt unknown
- 2018-08-23 SM SM20220169T patent/SMT202200169T1/it unknown
- 2018-08-23 US US16/639,902 patent/US11560374B2/en active Active
- 2018-08-23 DK DK18759105.2T patent/DK3672962T3/da active
- 2018-08-23 AU AU2018320419A patent/AU2018320419B2/en active Active
- 2018-08-23 CN CN202310448700.6A patent/CN116444510A/zh active Pending
- 2018-08-23 WO PCT/EP2018/072791 patent/WO2019038390A1/en not_active Ceased
- 2018-08-23 TW TW107129499A patent/TWI803511B/zh not_active IP Right Cessation
- 2018-08-23 EP EP22153292.2A patent/EP4056569A1/en not_active Withdrawn
- 2018-08-23 IL IL302077A patent/IL302077A/en unknown
- 2018-08-23 RS RS20220357A patent/RS63109B1/sr unknown
- 2018-08-23 PT PT187591052T patent/PT3672962T/pt unknown
- 2018-08-23 HR HRP20220497TT patent/HRP20220497T1/hr unknown
- 2018-08-23 JP JP2020510087A patent/JP7199736B2/ja active Active
- 2018-08-23 PL PL18759105T patent/PL3672962T3/pl unknown
- 2018-08-23 CN CN201880060742.XA patent/CN111108102B/zh active Active
- 2018-08-23 ES ES18759105T patent/ES2910157T3/es active Active
- 2018-08-23 TW TW112116474A patent/TW202348601A/zh unknown
- 2018-08-23 HU HUE18759105A patent/HUE058661T2/hu unknown
- 2018-08-23 SI SI201830624T patent/SI3672962T1/sl unknown
- 2018-08-23 CN CN202310448740.0A patent/CN116462674A/zh active Pending
- 2018-08-23 EP EP18759105.2A patent/EP3672962B1/en active Active
- 2018-08-23 KR KR1020207007564A patent/KR102732013B1/ko active Active
-
2020
- 2020-02-20 IL IL272815A patent/IL272815B/en unknown
-
2022
- 2022-04-14 CY CY20221100283T patent/CY1125117T1/el unknown
- 2022-04-25 IL IL292489A patent/IL292489B2/en unknown
- 2022-12-13 JP JP2022198452A patent/JP2023021268A/ja not_active Ceased
- 2022-12-19 US US18/084,208 patent/US20230234949A1/en not_active Abandoned
-
2023
- 2023-12-22 AU AU2023285995A patent/AU2023285995A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123349T1 (el) | Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη | |
| CY1125245T1 (el) | Ετεροκυκλικες ενωσεις ως αναστολεις ρι3κ-γαμμα | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| CY1123561T1 (el) | Ενωσεις χρησιμες ως αναστολεις κινασης | |
| CY1125138T1 (el) | Ενωσεις πυριδυλπυριδονης | |
| EA201991503A1 (ru) | Производные пиразола в качестве ингибиторов malt1 | |
| AU2018320418A1 (en) | Pyridinamine-pyridone and pyrimidinamine-pyridone compounds | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| EA202092086A1 (ru) | Ингибиторы аргиназы | |
| EA202092907A1 (ru) | Мультиспецифические связывающие белки и их усовершенствования | |
| CY1125047T1 (el) | Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης | |
| EA202091484A1 (ru) | 4-азаиндольные соединения | |
| EA201890857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| CL2019001740A1 (es) | Novedoso conjugado de amanitina. | |
| EA201791507A1 (ru) | Пирроло- и пиразолопиримидины в качестве ингибиторов убиквитин- специфичной протеазы 7 | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| CY1124704T1 (el) | Παραγωγα sobetirome | |
| CY1125117T1 (el) | Ενωσεις μορφολινυλπυριδονης | |
| EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| EA201990598A1 (ru) | Высококонцентрированные низковязкие препараты ингибирующего masp-2 антитела, наборы и способы | |
| CY1125169T1 (el) | ΕΝΩΣΕΙΣ ΑΜΙΝΟΠΥΡΑΖΙΝΟ ΔΙΟΛΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΡΙ3Κ-γ | |
| UA117364C2 (uk) | Похідні аматоксину | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| CY1123285T1 (el) | Ενωσεις 6-αρυλ-4-(μορφολιν-4-υλ)-1η-πυριδιν-2-ονης χρησιμες για τη θεραπεια καρκινου και διαβητη | |
| EA201791768A1 (ru) | Иммуномодулирующие агенты |